Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May 22:18:5.
doi: 10.1186/s12907-018-0072-5. eCollection 2018.

B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report

Affiliations
Case Reports

B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report

Osamu Imataki et al. BMC Clin Pathol. .

Abstract

Background: Chronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma. CLL progresses slowly over years, but it eventually transforms to a more aggressive lymphoma such as the diffuse large B-cell (DLBCL) type, also known as Richter's syndrome.

Case presentation: We treated a 69-year-old Japanese male who was histologically diagnosed with Richter's syndrome after 6 years of CLL. His lymphadenopathy had systemically progressed for years, with lymphocyte counts of less than 10,000 cells/μL and a disease status of Rai classification stage I and Binet classification B. He had high fever and hepatosplenomegaly upon Richter's transformation. The patient was treated with ofatumumab for refractory CLL, which relieved his febrile lymphadenopathy. He received a total of 11 ofatumumab courses and achieved partial remission. On the day of the 12th course of ofatumumab, his disease relapsed with febrile lymphadenopathy. Computed tomography revealed multiple liver masses and systemic lymphadenopathy, while a liver biopsy confirmed T-cell lymphoma. Concomitantly, CD20-lacking CLL cells were detected in his peripheral blood and bone marrow, and pathological examination of his left cervical lymph node biopsy showed CD20-positive DLBCL. The final diagnosis was three different types of lymphoma pathologies: (1) CD20-positive DLBCL of the lymph nodes, (2) CD20-lacking CLL of the peripheral blood and bone marrow, and (3) peripheral T-cell lymphoma (PTCL) of the liver. He received intravenous and oral dexamethasone therapy as palliative care. He died because of the rapid progression of abdominal masses 2 months after the diagnosis of triple transformation CLL. An autopsy revealed aggressive PTCL with aggressive systemic involvement of the liver, spleen, gall bladder, pericardium, bone marrow, and mediastinal-paraaortic-intraceliac lymph nodes. T-cell receptor study of an autopsy specimen supported the diagnosis of PTCL that spread to the intraceliac organs and lymph nodes. We concluded that his pathogenicity progressed to a mixture of triple lymphoma as a result of double malignant transformations, which included PTCL from CLL, CD20-negative CLL, and CD20-positive DLBCL by Richter's transformation.

Conclusions: Our case provides information on the biology of CLL, to transform from a low-grade chemosensitive status to a malignant chemoresistant status.

Keywords: Chronic lymphocytic leukemia (CLL); Ofatumumab; Richter’s syndrome; Transformation.

PubMed Disclaimer

Conflict of interest statement

The study protocol was approved by the Institutional Review Board of Kagawa University Hospital (approval number H23–23).Written informed consent was obtained from the patient for publication of this Case Report and all accompanying images. A copy of the written consent is available for review from the Editor-in-Chief of this journal.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Pathology of CD20-positive diffuse large B-cell lymphoma from the lymph nodes biopsy. EBV was negative. Cervical lymph node biopsy showed diffuse growth of mid-sized lymphocytes. Immunohistochemical analysis revealed proliferating lymphoma cells that were positive for CD20, CD79α, and CD5, but negative for CD3
Fig. 2
Fig. 2
Pathology of CD20-lacking chronic lymphocytic leukemia in the bone marrow biopsy. Bone marrow biopsy revealed hypercellular marrow with diffuse proliferation of small-sized lymphocytes. Immunohistochemical analysis revealed that the proliferating lymphoma cells were positive for CD79α and CD5, but negative for CD20
Fig. 3
Fig. 3
Pathology of peripheral T-cell lymphoma from the liver biopsy. Liver biopsy revealed mid- to large-sized atypical lymphocytes that were phenotypically T cells, positive for CD3, CD5, CD8, and CD45RO with diffuse growth. Lymphoma cells infiltrated the Glisson’s sheath. (CLL; chronic lymphocytic leukemia, DLBCL; diffuse large B-cell lymphoma, PTCL; peripheral T-cell lymphoma)

Similar articles

Cited by

References

    1. Rossi D. Richter's syndrome: novel and promising therapeutic alternatives. Best Pract Res Clin Haematol. 2016;29(1):30–39. doi: 10.1016/j.beha.2016.08.006. - DOI - PubMed
    1. Jain P, O'Brien S. Richter's transformation in chronic lymphocytic leukemia. Oncology (Williston Park) 2012;26(12):1146–1152. - PubMed
    1. Jamroziak K, Tadmor T, Robak T, Polliack A. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015;56(7):1949–1958. doi: 10.3109/10428194.2014.979411. - DOI - PubMed
    1. Martinez A, Pittaluga S, Villamor N, Colomer D, Rozman M, Raffeld M, Montserrat E, Campo E, Jaffe ES. Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis. Am J Surg Pathol. 2004;28(7):849–858. doi: 10.1097/00000478-200407000-00002. - DOI - PubMed
    1. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Safety RT. Efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094–1100. doi: 10.1182/blood-2007-09-111781. - DOI - PubMed

Publication types

LinkOut - more resources